Finch Therapeutics Group Past Earnings Performance
Past criteria checks 0/6
Finch Therapeutics Group's earnings have been declining at an average annual rate of -34.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 69.9% per year.
Key information
-34.3%
Earnings growth rate
16.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -69.9% |
| Return on equity | -326.6% |
| Net Margin | -69,863.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Revenue & Expenses BreakdownBeta
How Finch Therapeutics Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -75 | 27 | 0 |
| 30 Sep 23 | 0 | -99 | 33 | 0 |
| 30 Jun 23 | 0 | -137 | 39 | 0 |
| 31 Mar 23 | 1 | -152 | 38 | 0 |
| 31 Dec 22 | 1 | -115 | 36 | 0 |
| 30 Sep 22 | 2 | -107 | 32 | 0 |
| 30 Jun 22 | 13 | -76 | 28 | 0 |
| 31 Mar 22 | 15 | -69 | 26 | 0 |
| 31 Dec 21 | 19 | -58 | 21 | 0 |
| 30 Sep 21 | 20 | -52 | 23 | 0 |
| 30 Jun 21 | 10 | -52 | 20 | 0 |
| 31 Mar 21 | 9 | -45 | 16 | 0 |
| 31 Dec 20 | 8 | -39 | 14 | 0 |
| 31 Dec 19 | 10 | -21 | 7 | 0 |
Quality Earnings: FNCH is currently unprofitable.
Growing Profit Margin: FNCH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FNCH is unprofitable, and losses have increased over the past 5 years at a rate of 34.3% per year.
Accelerating Growth: Unable to compare FNCH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FNCH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: FNCH has a negative Return on Equity (-326.64%), as it is currently unprofitable.